இணைந்து வருவாய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இணைந்து வருவாய். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இணைந்து வருவாய் Today - Breaking & Trending Today

Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress

Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Dineshv Patel , Janssen Biotech Inc , Prnewswire Protagonist Therapeutics Inc , European Hematology Association , Protagonist Therapeutics Inc , Exchange Commission , Development Rd Expenses , Drug Administration Breakthrough Therapy Designation , Virtual Congress , Chief Executive , Drug Administration , Breakthrough Therapy , Subcutaneous Injectable Hepcidin Mimetic , Polycythemia Vera , Breakthrough Therapy Designation , Janssen Biotech , Protagonist Collaboration , Cash Equivalents , Marketable Securities , Collaboration Revenue , Private Securities Litigation Reform Act , Consolidated Statements , Months Ended , ஒன்றுபட்டது மாநிலங்களில் , ஜான்சன் பயோடெக் இன்க் ,

Nirsevimab MEDLEY Phase II/III trial demonstrated favourable safety and tolerability profile in infants

Nirsevimab MEDLEY Phase II/III trial demonstrated favourable safety and tolerability profile in infants
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

New York , United States , United Kingdom , Sanofi Pasteur , Joseph Domachowske , Astrazeneca Synagis , Drug Administration , European Medicines Agency Priority , Company On Twitter Astrazeneca , Global Head Of Research , University Of New York , National Medical Products Administration , China Center , State University , Upstate Medical Center , Executive Vice President , Global Head , Breakthrough Therapy Designation , Drug Evaluation , European Medicines Agency , Between July , Southern Hemispheres , Collaboration Revenue , Swedish Orphan Biovitrum , Biologics License Application , புதியது யார்க் ,

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Nirsevimab PhII/III trial confirms safety profile

and tolerability profile in infants at high risk of RSV

The MEDLEY Phase II/III trial evaluated the safety and tolerability of nirsevimab compared to Synagis (palivizumab) when given to infants at high risk of respiratory syncytial virus (RSV) entering their first RSV season.
1

The trial assessed the safety of nirsevimab in infants with chronic lung disease (CLD), congenital heart disease (CHD) and/or prematurity. Occurrence of treatment emergent adverse events (TEAEs) or treatment emergent serious adverse events (TESAEs) were similar between groups.
1

Nirsevimab is a long-acting antibody, using AstraZeneca s proprietary YTE technology, being developed by AstraZeneca and Sanofi with the potential ....

New York , United States , United Kingdom , Sanofi Pasteur , Joseph Domachowske , Astrazeneca Synagis , Adrian Kemp , Hospitalizations Among Children Aged Lancet Glob Health , Centers For Disease , Drug Administration , European Medicines Agency Priority , Company On Twitter Astrazeneca , Global Head Of Research , University Of New York , Investor Relations Team , National Medical Products Administration , Burden Of Community , Oxford Vaccines Group , China Center , State University , Upstate Medical Center , Executive Vice President , Global Head , Breakthrough Therapy Designation , Drug Evaluation , Breakthrough Therapy Designationfrom ,

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Nirsevimab Phase III trial met primary endpoint

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Nirsevimab Phase III trial met primary endpoint
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Sanofi Pasteur , William Muller , Jean Franois Toussaint , Ann Roberth Lurie , Adrian Kemp , European Medicines Agency Priority , Northwestern University Feinberg School Of Medicine , Company On Twitter Astrazeneca , Global Head Of Research , Burden Of Community , Oxford Vaccines Group , American Academy Of Pediatrics Immunoprophylaxis , China Center , Centers For Disease , Drug Administration , Community Trials , Investor Relations Team , National Medical Products Administration , Lancet Glob Health , Associate Professor , Northwestern University Feinberg School , Scientific Director , Executive Vice President , Franois Toussaint ,

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
Regulatory guidance anticipated in the first half of 2021 for registrational clinical development plan of investigational drug, rusfertide (PTG-300), for polycythemia vera
Company expects to share findings from ongoing hereditary hemochromatosis study for rusfertide (PTG-300) in the second half of 2021
Strong cash position to fund planned operations through the first half of 2024
Management to host conference call today at 4:30 p.m. EST
News provided by
Share this article
Share this article
NEWARK, Calif., March 10, 2021 /PRNewswire/ Protagonist Therapeutics, Inc. ( Protagonist or the Company ) (Nasdaq: PTGX) today reported financial results and provided a corporate update for the fourth quarter and full year ended December 31, 2020. ....

United States , Dineshv Patel , Company Nasdaq , Prnewswire Protagonist Therapeutics Inc , Drug Administration , Protagonist Therapeutics Inc , American Society Of Hematology , Exchange Commission , Development Rd Expenses , European Medicines Agency , Protagonist President , Chief Executive , Fast Track , Red Blood Cells , American Society , Cash Equivalents , Marketable Securities , Collaboration Revenue , Private Securities Litigation Reform Act , Annual Report , Consolidated Statements , Protagonist Therapeutics , Health Care Amp Hospitals , Medical Pharmaceuticals , ஒன்றுபட்டது மாநிலங்களில் , நிறுவனம் நாஸ்டாக் ,